Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177450 | 1.00 | CTSK (0.36) | CTSKCTSSCA12CA14MAPT | |
| SCHEMBL12175329 | 1.00 | CTSK (0.36) | CTSKCTSSCA12CA14MAPT | |
| SCHEMBL8915391 | 0.86 | CTSL (0.33) | CTSSACACBEPHX1MMP1MMP2 | |
| SCHEMBL12231936 | 0.86 | CTSL (0.33) | CTSSACACBEPHX1MMP1MMP2 | |
| SCHEMBL12630175 | 0.84 | ALOX15 (0.39) | CTSKCTSSSMN1; SMN2NPSR1 | |
| SCHEMBL19364746 | 0.84 | PLA2G2A (0.37) | CTSKCTSSCA12CA14MAPT | |
| SCHEMBL19364692 | 0.84 | PLA2G2A (0.37) | CTSKCTSSCA12CA14MAPT | |
| SCHEMBL19485881 | 0.84 | PLA2G2A (0.37) | CTSKCTSSCA12CA14MAPT | |
| SCHEMBL18653057 | 0.84 | ACACB (0.32) | ACACB | |
| SCHEMBL19323904 | 0.84 | ACACB (0.32) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10407445-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2017112531-A1 | SILANE-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9555038-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| EP-2545060-B1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| EP-2516430-B1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014110706-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110705-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110687-A1 | THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013039878-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2010138791-A1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSK 632/4885CTSS 445/4885CA12 4401/4885 |
| US-10407445-B2 | Hepatitis C virus inhibitors | HAVCR2, SLC10A1, EIF2AK2 | CTSK 944/4885CTSS 590/4885CA12 3053/4885 |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | HAVCR2, SULT2A1, HBB | CTSK 3694/4885CTSS 2199/4885CA12 978/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSK 632/4885CTSS 445/4885CA12 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.